MYC and colorectal cancer: Other studies found that Dot1l epigenetically promoted the transcription of c-Myc via H3K79me2, while silence or inhibition of Dot1l induced cell cycle arrest in colorectal cancer cells, suggesting that Dot1l inhibitor might be a potential drug for the treatment of colorectal cancer [19].